~~<i id='FB138D66B1'><strike id='FB138D66B1'><tt id='FB138D66B1'><pre id='FB138D66B1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：leisure time 2025-10-04 03:59:20 - browse：41

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

focus

knowledge

focus

explore

hotspot

UnitedHealthGroupCEOAndrewWittysaidthecompanywasbeginningtoseea“disturbance”initsMedicaidmedicalcost

WSS

NIH trials fail to test meaningful long Covid therapies, experts say

Anavex keeps shifting the goalposts in its clinical trials

Structure Therapeutics oral GLP

Senators tussle over abortion against the backdrop of a presidential campaign

BD to buy Edwards patient monitoring unit for $4.2 billion

An outdated Medicare rule harms dementia patients with anxiety

focus

focus

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Emergent cuts jobs, executive role in business shake

FDA approval of Sarepta Duchenne genetic therapy gives me hope

American woman, child freed after being kidnapped in Haiti last month

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Take antibiotics after sex, CDC recommends for certain risk groups

Peter Hotez and the public health issue of online harassment

Friends ask where James Watson's attitudes about race came from

Sports medicine is finally prioritizing gender equality

Anthony Fauci pushes back on GOP claims during Covid hearing

knowledge

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Naloxone nonprofit donates 200,000 doses after FDA approval

FDA panel issues narrow recommendation for Covid vaccine booster doses

Elevance PBM president out as customers face prescription chaos

Why failed clinical trials don’t always spell doom for a new drug

Drastic changes should bring profitability, startup health insurers say

focus

focus

explore

hotspot